Durata Therapeutics Inc (NASDAQ:DRTX)
| 7.12 Data as of May 24 |  +0.06 / +0.85%Today’s Change | 6.65 Today|||52-Week Range 10.63 | -6.81% Year-to-Date |
Latest DRTX News | Press Releases
No recent news for Durata Therapeutics Inc.
Today’s Trading
| Previous close | 7.06 |
| Today’s open | 7.02 |
| Day’s range | 7.00 - 7.16 |
| Volume | 25,204 |
| Average volume (3 months) | 69,676 |
| Market cap | $189.6M |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/24/2013
Growth & Valuation
| Earnings growth (last year) | -261.47% |
| Earnings growth (this year) | +68.45% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | 2.98 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| AMPEAmpio Pharmaceutical... | -0.02 | -0.39% |
| ACSTAcasti Pharma Inc | 0.00 | 0.00% |
| CORTCorcept Therapeutics... | +0.04 | +2.21% |
| SVASinovac Biotech Ltd | -0.04 | -1.19% |
Data as of 4:00pm ET, 05/24/2013
Financials
| Next reporting date | September 3, 2013 |
| EPS forecast (this quarter) | -$0.56 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$62.5M |
| Net profit margin | -- |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Other |
President, Chief Executive Officer & Director Paul R. Edick |
COO, CFO, Secretary & Treasurer Corey N. Fishman |
Corporate headquarters Chicago, Illinois |
Forecasts
